Structure and Dimerization of the Kinase Domain from Yeast Snf1, a Member of the Snf1/AMPK Protein Family  by Nayak, Vinod et al.
Structure 14, 477–485, March 2006 ª2006 Elsevier Ltd All rights reserved DOI 10.1016/j.str.2005.12.008Structure and Dimerization of the Kinase
Domain from Yeast Snf1, a Member
of the Snf1/AMPK Protein FamilyVinod Nayak,1,2 Kehao Zhao,1 Anastasia Wyce,1,3
Marc F. Schwartz,1Wan-Sheng Lo,1 Shelley L. Berger,1
and Ronen Marmorstein1,2,*
1The Wistar Institute
2Department of Chemistry
University of Pennsylvania
3University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania 19104
Summary
The Snf1/AMPK kinases are intracellular energy sen-
sors, and the AMPK pathway has been implicated in
a variety ofmetabolic human disorders. Herewe report
the crystal structure of the kinase domain from yeast
Snf1, revealing a bilobe kinase fold with greatest ho-
mology to cyclin-dependant kinase-2. Unexpectedly,
the crystal structure also reveals a novel homodimer
that we show also forms in solution, as demonstrated
by equilibrium sedimentation, and in yeast cells,
as shown by coimmunoprecipitation of differentially
tagged intact Snf1. A mapping of sequence conserva-
tion suggests that dimer formation is a conserved fea-
ture of the Snf1/AMPK kinases. The conformation of
the conserved aC helix, and the burial of the activation
segment and substrate binding site within the dimer,
suggests that it represents an inactive form of the ki-
nase. Taken together, these studies suggest another
layer of kinase regulation within the Snf1/AMPK fam-
ily, and an avenue for development of AMPK-specific
activating compounds.
Introduction
Members of the Snf1/AMP-activated kinase (AMPK)
family are conserved in all eukaryotes and play funda-
mental roles in cellular responses to metabolic stress
(Carling, 2004; Hardie et al., 1998). While mammals, in-
sects, nematodes, and plants have multiple genes en-
coding AMPK homologs, yeast has only the one SNF1
gene. Yeast Snf1 and mammalian AMPK are the most
extensively studied members of this protein family. Mul-
tiple stress signals elevate the AMP-to-ATP ratio, which
in turn results in the activation of AMPK to switch off
ATP-consuming anabolic pathways and to switch on
ATP-producing catabolic pathways. AMPK is also acti-
vated by leptin, a hormone that regulates food intake
(Minokoshi et al., 2002), and metformin, a drug used to
treat type-II diabetes (Zhou et al., 2001). In addition, mu-
tations in the g2 regulatory subunit of AMPK produce
a cardiac disease in humans called Wolf-Parkinson
syndrome (Arad et al., 2002), and LKB1, a target of inac-
tivating mutations in a dominantly inherited cancer in
humans termed Peutz-Jeghers syndrome, has been
identified as an AMPK upstream kinase (Woods et al.,
2003). Because of these correlations with disease,
*Correspondence: marmor@wistar.orgAMPK has received considerable attention as a possible
target for the development of compounds that might
regulate its activity for therapeutic application (Clap-
ham, 2004).
In the yeast Saccharomyces cerevisiae, Snf1 (sucrose
nonfermenting 1) is also required for stress responses
and, most notably, the adaptation of cells to carbon
stress (Sanz, 2003). For example, cells growing in high
glucose maintain Snf1 in an inactive state. However,
when the glucose levels are depleted, Snf1 is activated
to regulate gene expression by phosphorylating several
different transcriptional regulators. For example, Snf1
inhibits the transcriptional repressor Mig1 (Treitel, 1998),
stimulates the transcriptional activators Cat8 and Sip4
(Hiesinger et al., 2001), and directly interacts with the
Srb/mediator proteins of the RNA polymerase holoen-
zyme (Kuchin et al., 2000).
Other studies have revealed another aspect of Snf1
function during stress response. Snf1 has been shown
to phosphorylate histone H3 in a promoter-specific
fashion (Lo et al., 2001; Lo et al., 2005). On a subset of
Gcn5-regulated promoters, such as the INO1, Snf1
phosphorylates serine 10 of histone H3 to promote sub-
sequent acetylation of Lys14 by the Gcn5 histone acetyl-
transferase. In addition to histone phosphorylation and
acetylation, histones have been shown to receive other
posttranslational modifications, including methylation
and ubiquitination (Ausio et al., 2001; Grant, 2001), and
the process by which coordinated modifications, such
as phosphorylation and acetylation leading to distinct
transcriptional events, has been described as the ‘‘his-
tone code’’ hypothesis (Strahl and Allis, 2000).
Genetic and biochemical studies have revealed that
Snf1 is the catalytic (a) subunit of a trimeric protein com-
plex, which, in addition to Snf1, contains one of thebsub-
units Sip1, Sip2, or Gal83, and theg subunit Snf4 (Halford
et al., 2004; Jiang and Carlson, 1997). Snf1 is a 633 amino
acid protein with a kinase domain of about 330 residues,
near the amino terminus. The C-terminal region of the
protein contains a regulatory domain that is involved in
binding other subunits of the complex. It has been shown
that b subunits regulate the nuclear and cytoplasmic lo-
calization of the Snf1 complex (Vincent et al., 2001), al-
though it is likely that they have other functions that are
more poorly characterized. The specific roles of the indi-
vidual b subunit proteins Sip1, Sip2, and Gal83 are not
well understood; however, the presence of at least one
b subunit is required for kinase function in vivo (Schmidt
and McCartney, 2000), and yeast strains expressing
a single b subunit show distinct phenotypes (Nath
et al., 2002). Therefore, the three distinct Snf1 complexes
formed appear to have specialized roles. The g subunit is
also essential for kinase activity in vivo (Jiang and Carl-
son, 1997; McCartney, 2001; Schmidt and McCartney,
2000). Previous studies have found that the trimeric
Snf1 complex is organized by the binding of theb subunit
to both theaand theg subunits (Jiang and Carlson, 1997;
Yang et al., 1994). The g subunit also binds the regulatory
domain of the Snf1 kinase in a glucose-regulated manner
(Jiang and Carlson, 1996). Thus, it appears that the b and
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478Figure 1. Structure of the Yeast Snf1 Kinase Domain
(A) The Snf1 dimer. The two protomers of the homodimer are shown in yellow and cyan. The ATP binding P loop (green), aC helix (orange), and
activation segment T loop (red) are each color coded, and disordered loops are indicated with dotted lines. Secondary structure notation is
based on the structure of PKA (Knighton et al., 1991). The image on the right is rotated by about 90º about a vertical axis between the two pro-
tomers.
(B) Electron density of the activation segment at the dimerization interface. Activation loop residues of one protomer are colored yellow, and
residues from the opposing protomer are colored cyan and labeled in italics. For clarity, only side chain atoms from the opposing protomer
are shown. Electron density from a composite omit map is contoured at 0.8s.
(C) Electron density of the aG helix at the dimerization interface. The image is centered around residues I257 and F261. The color coding and
contour level is as described in Figure 1B.g subunits regulate Snf1 kinase activity and also confer
substrate specificity.
In this study, we report the X-ray crystal structure of
the kinase domain of Snf1. The Snf1 kinase domain re-
veals a typical bilobe kinase fold, with the greatest struc-
tural similarity to cyclin-dependant kinase-2. In addition,
the crystals reveal a novel homodimeric structure that
we show also forms in solution and in yeast cells. Based
on sequence conservation, Snf1 dimerization appears
to be a conserved feature of the Snf1/AMPK family
kinases. Several structural features suggest that this di-
mer represents an inactive form of the kinases and thus
another layer of regulation of the Snf1/AMPK kinases.
Results
Overall Structure of the Snf1 Kinase Domain
The 33 kDa Snf1 kinase domain (residues 33–320) was
overexpressed in bacteria and purified to homogeneity
using a combination of cation exchange and gel filtration
chromatography, where the protein eluted between the
44 and 158 kDa molecular weight standards on a Super-
dex-75 column, suggestive of a protein dimer. The pro-
tein crystallized in space group P4212 containing onemolecule per asymmetric unit cell and, consistent with
the gel filtration data, the crystals contain a crystallo-
graphically related dimer containing 3000 A˚2 of solvent
excluded surface at the dimer interface (Figure 1A).
The structure was determined to 2.8 A˚ resolution using
multiple wavelength anomalous diffraction (MAD) from
selenomethionine-derivatized protein (Table 1).
The kinase domain adopts an elongated bilobe struc-
ture that is typical of all kinases. A smaller b-rich
N-terminal lobe contains the b3 strand and helix aC har-
boring the conserved phosphate binding residues Lys84
and Glu103, respectively, and the ATP binding P loop
(residues 61–69); and a larger helical-rich C-terminal
lobe contains the catalytic Asp177 residue (Figures 1A
and 2). The active site, containing the majority of the
ATP binding residues and the T loop activation segment
(Figure 1B), is located in a groove formed between the
two lobes. The two subunits of the crystallographic di-
mer cross at a roughly 45º angle, with the N-terminal
lobe of one subunit proximal to the C-terminal lobe of
an opposing subunit, and the dimer interface formed
by Snf1/AMPK conserved hydrophobic residues and
residues within the T loop activation segment (residues
195–221) from both protomers (Figures 1A–1C).
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479Table 1. Data Collection, Phasing, and Refinement
Crystal parameters
Space group P4212
Unit cell (native) a = b = 108.67, c = 61.50
Data collection Peak Inflection Remote Native
Wavelength (A˚) 0.97940 0.97959 0.96863 0.97959
Resolution (A˚) 50–3.0 50–3.0 50–3.0 50–2.8
Total reflections 499,502 507,113 513,519 378,898
Unique reflections 7,774 7,778 14,080 11,830
Completeness (%)a 100 (100) 100 (100) 100 (100) 99.8 (100)
Avg. I/s 42.5 (7.6) 36.97 (5.8) 31.5 (5.17) 34.3 (4.3)
Rmerge (%)
b 10.3 (48.5) 10.1 (63.3) 8.6 (49.9) 7.1 (52.4)
Refinement statistics
Resolution range, A˚ 50–2.8
R(working), % 22.3
R(free), % 26.5
Rmsds from ideal
Bond lengths (A˚) 0.007
Bond angles (º) 1.374
Baverage (A˚
2) No. of atoms
Protein 52.27 2057
Water 49.51 105
a Values in parenthesis are from the highest resolution shell.
b Rmerge =
PjI 2 <I>j/P<I>.Comparison with Other Kinases
A comparison of the Snf1 kinase with other protein ki-
nases shows the greatest structural superposition withcyclin-dependent kinase-2 (CDK2) (Figure 3A), with an
rmsd between Ca atoms of 1.7 A˚. CDK2 is inactive on
its own, but is activated upon binding to a cyclin protein.Figure 2. Sequence Alignment of Snf1/AMPK
Kinases
Sequences from yeast (Sc: S. cerevisiae), fly
(Dm = Drosophila melanogaster), human
(Hs = Homo sapiens), rat (Rn = Rattus norve-
gicus), worm (Ce = Caenorhabditis elegans)
and plant (At = Arabidopsis thaliana) were
aligned. Snf1 residue numbers are shown at
intervals of 10, and Snf1 secondary structure
elements are indicated above the alignment.
The P loop sequence is denoted by a green
bar and the activation T loop sequence by
a red bar. Residues involved in the dimeriza-
tion interface are denoted by triangles above
the alignment.
Structure
480Figure 3. Comparison of Snf1 and CDK2 Kinase Domains
(A) Overall superposition of nascent Snf1, nascent CDK2 and cyclin-bound CDK2 structures.
(B) Close-up view of interactions mediated by aC helix. Cyclin A binding induces a conformation change in the aC helix, leading to the formation
of the Lys33-Glu51 hydrogen bond that is associated with CDK2 activation.The crystal structures of both the inactive and a cyclin A
bound active form of the CDK2 kinase have been previ-
ously determined (De Bondt et al., 1993; Jeffrey et al.,
1995). Of particular interest is the conformation of the
conserved aC helix in the N-terminal lobe that adopts
two different orientations, dependent on the activation
state of the kinase. In active CDK2, the bound cyclin
molecule interacts with the aC helix and positions it
close to the active site such that a conserved glutamate
residue (Glu51 in CDK2) is oriented to form a hydrogen
bond with a conserved lysine residue (Lys33 in CDK2)
within the b3 strand, which in turn enables the kinase
to bind ATP (Figure 3B). In the inactive cyclin-free
form, the aC helix of CDK2 is rotated away from the ac-
tive site such that Glu51 and Lys33 cannot hydrogen
bond, thus destabilizing ATP binding, rendering the ki-
nase inactive. In the Snf1 kinase, the corresponding
ATP binding residues are Glu103 and Lys84. A superpo-
sition of the CDK2 and Snf1 kinase domains reveals that
the aC helix containing Glu103 has a conformation that
closely resembles the inactive form of CDK2 (Figures
3A and 3B). In addition, the Lys 84 and Glu103 side
chains in Snf1 are disordered. This correlation suggests
that the Snf1 kinase domain monomer structure that we
have determined is in the inactive form.
Interestingly, while all kinases show a comparable
Lys-Glu hydrogen bonding network in the active form
of the corresponding kinase, the activity of other kinases
is also regulated, in part through the allosteric modula-
tion of the aC helix orientation. For example, the aC helix
of the Src tyrosine kinase is held in an inactive confor-
mation by intramolecular interactions with the SH2 and
SH3 domains, and the phosphorylation-dependent dis-
engagement of these domains from the kinase domain
results in a reorientation of the aC helix into an active
conformation (Huse and Kuriyan, 2002). Based on these
correlations and the observation that the Snf1 kinase re-
quires association with its b and g subunits for in vivo ac-
tivity (Sanz, 2003; Schmidt and McCartney, 2000), we
propose that one of the roles of one or more of these
subunits may be to reorient the aC helix into an active
conformation.The Dimer Interface
As noted above, the crystal structure of the Snf1 kinase
reveals a crystallographic dimer containing an extensive
dimerization interface (Figures 1A and 1C). This dimer-
ization interface buries a total solvent-excluded surface
of 1500 A˚2, and a Lawrence and Colman goodness of
fit calculation gives a value of 0.575 (Lawrence and
Colman, 1993), both indicative of a significant dimer in-
terface. The physiological relevance of this interface is
supported by the observation that the most highly con-
served region of the Snf1/AMPK family maps to this in-
terface (Figures 2 and 4A). The dimer interface is formed
predominately by hydrophobic interactions involving
residues within the T loop activation segment and the
loop-aG region of the kinase domain. The T loop acti-
vation segment-mediated interactions are centered
around Thr210, the target of upstream Snf1 activating ki-
nases, and involve the flanking residues Phe 207, Ile 208,
Cys 212, and Pro 215 (Figure 4B). The methyl group of
Thr 210 makes van der Waals contacts to the Leu 250
side chain of the symmetry-related Snf1 subunit of the
dimer. In addition, residues Phe 207 and Ile 208 make
van der Waals contacts to the aliphatic arm of Arg 248
and the Phe 140, Val 144, and Val 244 side chains of
the Snf1 symmetry-related subunit; and residues Cys
212 and Pro 215 make van der Waals interactions with
the symmetry-related Snf1 side chains Pro215, Ile 250,
and Ile 257. The loop-aG interactions centered around
Ile 257 and Phe 261 mediate van der Waals contacts to
the same residues of the symmetry-related Snf1 subunit
of the dimer, and also include the symmetry-related res-
idues Pro 215, Ile 223, and Cys 212 (Figure 4C). Strik-
ingly, nearly all of the residues that mediate dimer inter-
actions are highly conserved within the Snf1/AMPK
family (Figure 2), thus implicating the functional impor-
tance of the crystallographically observed dimer within
the Snf1/AMPK protein family.
A striking feature of the Snf1 dimer observed in the
crystals is that Thr 210 is highly buried and inaccessible
for phosphorylation by an activating upstream kinase
(Figures 1A, 1B, and 4A). In addition, a modeling of ATP
and protein peptide substrate onto the Snf1 structure
Structure of Snf1 Kinase
481Figure 4. The Crystallographic Snf1 Dimer
(A) Mapping of strictly conserved Snf1/AMPK residues (gray) onto the molecular surface of the kinase domain monomer. Side chain residues that
mediate dimer interactions are highlighted in green, and the aG helix and activation segment from the opposing protomer are included in blue
schematic with green side chains. The residues from the opposing subunit of the dimer that play key roles in dimer formation are also highlighted
as green side chains.
(B) Close-up of the burial of the activation loop residue T210 within the Snf1 kinase domain dimer. The activation loop of one protomer is shown in
yellow with side chains in green. Secondary structure elements of the opposing protomer are shown in blue and side chains in cyan are labeled in
italics.
(C) Close-up view of dimer interactions mediated by the aG helix and activation segment.based on a superposition of Snf1 with a CDK2/ATP/pro-
tein peptide complex also suggests that the dimer is not
compatible with cosubstrate binding. Specifically, while
ATP can be modeled onto Snf1 without steric clash, the
peptide substrate would make a direct clash with resi-
dues 210–212 of the activation segment from the other
protomer of the dimer (Figure 5). Taken together, these
observations support the hypothesis that the crystallo-
graphically observed Snf1 dimer represents an inactive
form of the kinase.
Oligomerization State of the Snf1 Kinase Domain
in Solution
The crystallographic Snf1 dimer is consistent with its
elution on gel filtration chromatography between the
44 and 158 kDa protein standards (Figure 6B). In order
to obtain a more definitive and quantitative characteriza-
tion of the solution oligomerization properties of the
Snf1 kinase domain, we performed equilibrium ultracen-
trifugation of the recombinant kinase domain (Figure 6A).
This analysis was carried out at three different centrifu-
gation speeds and three different protein concentra-
tions. Global analysis of these data reveals an excellent
fit for a homodimer, with no detectable dissociation to
a monomer under the conditions used. These data are
consistent with the gel filtration and crystallographic
data. To further validate the biological significance of
the specific Snf1 dimer seen in the crystals, we preparedtwo site-directed mutations predicted from the crystal-
lographic dimer to disrupt dimer contacts and analyzed
these mutants by gel filtration analysis. The Snf1 posi-
tions that were chosen for mutagenesis were Ile 257
and Phe 261, two key hydrophobic residues that stabi-
lize the crystallographic Snf1 kinase domain dimer (Fig-
ure 4). These positions were mutated to glutamate resi-
dues (I257E and F261E) in an attempt to disrupt this
hydrophobic core of the dimer interface. Each of these
mutants were prepared by site-directed mutagenesis
and purified essentially as described for the native re-
combinant protein, and then analyzed by gel filtration
chromatography. As shown in Figure 6B, the F261E
Snf1 mutant elutes as two peaks from gel filtration, cor-
responding to a monomeric and dimeric Snf1 species,
and I257E elutes almost exclusively at a position corre-
sponding to an Snf1 monomer. Taken together, the so-
lution studies on the Snf1 kinase domain show that, as
in the crystals, the kinase domain forms a tight dimer.
Moreover, the mutational sensitivity of the I257E and
F261 for dimer formation is consistent with the physio-
logical relevance of the crystallographic Snf1 dimer.
Self-Association of Full-Length Snf1 in Yeast Cells
In order to probe in vivo self-association of Snf1 mole-
cules, we carried out coimmunoprecipitation experi-
ments in yeast cells. For these experiments, we pre-
pared a yeast strain harboring two alternatively tagged
Structure
482Figure 5. Model for Snf1 Interaction with ATP and Protein Peptide Substrates
(A) Model of Snf1 kinase domain with ATP and substrate peptide superimposed from the crystal structure of active CDK2 with substrate (Brown
et al., 1999). The placement of the ATP and peptide substrates is based on the superposition of the kinase domains. The ATP is shown in gray and
peptide is shown in red.
(B) The opposing subunit (schematic in cyan) of the Snf1 kinase domain dimer is mapped onto the model in (A) to illustrate the occlusion of the
peptide substrate binding site within the Snf1 kinase domain dimer.(HA and FLAG) full-length Snf1 proteins encoded on
separate plasmids, grew the yeast strain, disrupted the
cells, and probed for self association using coimmun-
precipitation. Immunoprecipitation was carried out
with anti-FLAG antibody, and immunoprecipitates were
extensively washed, followed by protein separation on
SDS-PAGE gels and detection by Western blotting using
either anti-HA or anti-FLAG antibodies. As can be seen
in Figure 6C, bands corresponding to HA-Snf1 and
FLAG-Snf1 were detected with about equal intensity.
Similar results were obtained when anti-FLAG precipi-
tates were washed with 50–400 mM NaCl, or if protein
was first immunoprecipitated with anti-HA and then
blotted with anti-FLAG (Figure 6C). Together, these ex-
periments show that intact Snf1 protein self-associates
in vivo, consistent with our in vitro solution studies and
crystallographic observation of a dimer of the Snf1 ki-
nase domain.
Interestingly, similar coimmunoprecipitation experi-
ments employing yeast strains encoding HA- and
FLAG-tagged mutants that disrupt dimerization of the
Snf1 kinase domain when assayed in vitro (I257E and
F261E), as well as a K84R control mutant in the Snf1
active site away from the dimerization interface, do not
show a significant disruption of Snf1 self-association
in vivo (Figure 6C), suggesting that the I257E and
F261E mutations are not sufficient to disrupt Snf1 self-
association in vivo. These results suggest that other re-
gions of intact Snf1, or possibly other subunits of the
heterotrimeric Snf1 complex that forms in vivo, may
also contribute to Snf1 self-association in vivo.
Discussion
We have presented the structure of the kinase domain
from yeast Snf1, a member of the Snf1/AMPK family of
kinases. The high degree of sequence conservation
among this family of kinases suggests that they have
highly homologous structure, and the structure pre-sented here is thus representative of the kinase family.
The structure of the monomeric unit adopts an aC helix
conformation that is representative of inactive kinases.
A novel feature of the Snf1 kinase domain, both in the
crystals and in solution, is that it adopts a dimeric struc-
ture that has not been seen in other kinases. There are
several reasons to believe that this dimeric Snf1 struc-
ture represents an inactive form of the kinase: (1)
Thr210, a residue within the activation segment that re-
quires phosphorylation for kinase activation, is buried
within the dimer interface, making it inaccessible for
phosphorylation by an upstream activating kinase; (2)
while ATP can be modeled onto the Snf1 without steric
clash, the modeling of peptide substrate reveals that it
makes a steric clash with the activation segment of the
kinase. Based on these observations, we propose that
activation of the Snf1 kinase involves the disruption or
rearrangement of the dimer. Together, there appears
to be three layers of regulation of Snf1/AMPK activation.
First, association must occur with the b and g subunits,
the kinase domain dimer must be destabilized, and Thr
210 within the activation segment must be phosphory-
lated. It is not clear what may trigger kinase dimer do-
main destabilization, but it is attractive to propose that
either the b or g subunit or another region of Snf1 itself
may do this, perhaps in a way similar to that in which cy-
clins activate CDK (Pavletich, 1999), or how phosphory-
lation of the C-terminal tail region of the Src kinase dis-
places the SH2 and SH3 domains in Src activation (Huse
and Kuriyan, 2002). Regardless of the detailed mecha-
nism, it would appear that some form of allosteric regu-
lation must take place in Snf1/AMPK activation and that
Snf1/AMPK kinase domain activation involves an addi-
tional layer of regulation that is distinct from other
kinases.
The observation of coimmunoprecipitation of full-
length Snf1 from yeast cells is consistent with dimeriza-
tion of the kinase domain within the Snf1 protein in vivo.
Interestingly, while the F261E and I257E mutants disrupt
Structure of Snf1 Kinase
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(A) Sedimentation equilibrium data for the native Snf1 kinase domain
fitted with data from nine curves (three protein concentrations at
three centrifugation speeds). A representative run at a centrifugation
speed of 16,000 rpm and protein concentration of 0.3 mg ml21 is
shown. The plots represent a single dimeric species model for which
all nine curves were fitted. The bottom panel shows the experimental
data (open circles) with the calculated fits (lines). The top panel rep-
resents the residuals of the fits.
(B) Size exclusion chromatography of native Snf1 and Snf1 mutants
I257E and F261E. Each of the proteins is chromatographed on
Superdex-75 at a concentration of about 15 mg/ml, and protein elu-
tion peaks were identified by UV absorption at 280 nm.
(C) Snf1 coimmunoprecipitation experiments from yeast cells en-
coding HA- and Flag-tagged full-length Snf1. The antibodies used
for the immunoprecipitation and Western blotting are indicated, as
well as the salt wash used for washing the immunoprecipitate prior
to Western analysis.dimerization of the kinase domain in vitro, our coimmu-
noprecipitation experiments reveal that these mutations
are not sufficient to disrupt Snf1 self-association in vivo.
This observation suggests that the Snf1-Snf1 associa-
tion may involve more than the Snf1 kinase domain inter-
face observed in the crystal structure. This interface
could involve regions of Snf1 outside the kinase domain,
such as the regulatory domain, and/or the b or g sub-
units of the Snf1 complex.
Mammalian Pak1 represents another structurally
characterized kinase that forms a homodimer. Like
Snf1, the Pak1 homodimer forms an autoinhibited com-
plex, although the mode of autoinhibition appears
distinct from Snf1. The structure of Pak1 reveals a
trans-inhibited homodimeric conformation, in which an
N-terminal inhibitory portion of one protomer binds to
and inhibits the catalytic domain of the other protomer,
and associated biochemical studies reveal that GTPase
interaction disrupts dimer formation and facilitates acti-
vation of the kinase (Parrini et al., 2002). Interestingly,
there are many more examples of kinases that contain
cis autoinhibitory domains. Although it is not clear if
there is a distinction between kinases that form autoin-
hibitory complexes in cis or in trans that might have par-
ticular biological ramifications, trans inhibition would be
expected to introduce another layer of kinase regulation
that involves protein oligomerization that might be ex-
ploited in vivo. Regardless of the mechanism of kinase
autoinhibition, it appears that there exists a greater di-
versity for kinase inhibition than for kinase activation,
and that this diversity might be exploited for the design
of kinase-specific regulatory compounds.
Because of the correlation between AMPK kinase ac-
tivity and several human disorders, including type II dia-
betes, obesity, cardiac disease, and cancer, and the
observation that pharmacological factors that are bene-
ficial in these disorders have been shown to act, at least
in part, through the activation of AMPK (Arad et al., 2002;
Minokoshi et al., 2002; Woods et al., 2003; Zhou et al.,
2001), there has been significant interest in the develop-
ment of small-molecule AMPK activators that might
have therapeutic application (Clapham, 2004). Although
there are several kinase-specific inhibitors that have
been developed for therapeutic purposes, the develop-
ment of kinase-specific activators are technically more
challenging (Noble et al., 2004). Our structural findings
on the Snf1/AMPK kinase domain suggest a strategy
for developing Snf1/AMPK activators that takes advan-
tage of the unique dimerization properties of these ki-
nases. Compounds that inhibit kinase domain dimeriza-
tion may thus relieve one layer of AMPK regulation, thus
facilitating AMPK-specific activation in AMPK-mediated
human disorders.
Experimental Procedures
Protein Overexpression and Purification
The wild-type kinase domain of Snf1 (residues 33–320) was cloned
into the pRSET overexpression vector with an upstream 15 base
pair insert encoding a MKAAA N-terminal sequence to enhance pro-
tein expression. The cloned kinase domain was expressed in BL21
(DE3) cells by induction with 0.5 mM IPTG at 15ºC. The protein
was purified using SP-sepharose cation exchange chromatography
followed by size-exclusion chromatography on a Superdex-75 gel
filtration column. Peak fractions from the gel filtration column were
Structure
484pooled and concentrated tow30 mg/ml by ultracentrifugation with
a Millipore microconcentrator, flash frozen, and stored at270ºC un-
til further use. Selenomethionine-derivatized protein was expressed
in B834 (DE3) cells grown in MOPS minimal media with seleno-
methionine and other amino acids at suggested concentrations
(Doublie, 1997). Purification of the selenomethionine-derivatized
protein was carried out essentially as described for the underiva-
tized protein. The single amino acid substitution mutants Snf1-
I257E and Snf1-F261E were prepared by site-directed mutagenesis
(QuikChange, Stratagene) and purified essentially as described for
the wild-type kinase domain.
Crystallization and Data Collection
Snf1 kinase domain crystals were obtained by vapor diffusion using
the hanging drop method. A 2 ml aliquot of the protein solution at
10 mg/ml in a buffer containing 20 mM HEPES, 100 mM NaCl,
10 mM b-mercaptoethanol was mixed with 2 ml of reservoir solution
containing 0.1 M Tris (pH 8.5), 0.2 M MgCl2, 24%–30% polyethylene
glycol 4000, and equilibrated over 500 ml of reservoir solution at
room temperature. The crystals grew over 3–4 days, and native
and selenomethionine-derivatized crystals grew to typical sizes of
4003 4003 50–100 mm and 1003 1003 50 mm, respectively. Crys-
tals were cryoprotected by transferring them into reservoir solution
supplemented with increasing amounts of glycerol to a final concen-
tration of 15% and flash frozen in liquid propane, at which point they
were stored in liquid nitrogen until data collection.
To remove possible artifacts from model bias, we determined the
structure of the Snf1 kinase domain using MAD rather than molecu-
lar replacement with other kinase domains as search models. Data
from native and selenomethionine crystals were collected at beam-
line SBC-19BM at the Advanced Photon Source, Argonne National
Laboratory. The native data was collected at l = 0.9696 A˚ and pro-
duced useable diffraction data to 2.8 A˚ resolution. A 3.0 A˚ MAD
data set was collected from a single selenomethionine-derivatized
crystal at three wavelengths (l1 = 0.9794 A˚, peak; l2 = 0.9796 A˚,
edge; l3 = 0.9686 A˚, remote). All data were processed with DENZO
and SCALEPACK, and the space group was determined to be P4212.
Structure Determination and Refinement
The structure of the Snf1 kinase domain was solved by MAD. The
program SOLVE was used to located five selenomethionine residues
and to phase the 3.0 A˚ electron density map. The map was improved
by solvent flattening using the program RESOLVE, and the program
O was used to build a molecular model of the protein into the elec-
tron density map using the selenomethionine positions as a guide.
The native data set was used to extend the resolution to 2.8 A˚,
and refinement employed the program CNS, using simulated an-
nealing and torsion angle dynamics protocols with subsequent man-
ual adjustment of the model, with reference to 2Fo-Fc, and differ-
ence maps, using the program O. Water molecules that showed
appropriate 2 s density peaks in Fo-Fc maps and that participated
in hydrogen bonds with protein residues or other water molecules
were added after the free R value dropped below 30%, and, toward
the end of refinement, atomic B-factors were refined. The final model
was checked for errors using composite simulated annealing maps.
The final model contains residues 46–319. Residues 90–97, 123–126
and 199–205 were not modeled due to poor electron density corre-
sponding to these regions. The final model has excellent refinement
statistics and stereochemical parameters (Table 1).
Analytical Ultracentrifugation and Gel Filtration Analysis
Sedimentation equilibrium experiments were performed with a
Beckman Optima XL1 ultracentrifuge at 4ºC, and in a buffer contain-
ing 20 mM HEPES, 100 mM NaCl, and 1 mM b-mercaptoethanol. The
protein samples were loaded in 6 sector 12 mm centerpieces. The
native Snf1 kinase domain samples were analyzed at concentrations
of 0.15, 0.30, and 0.60 mg/ml, and each protein concentration was
analyzed at centrifugation speeds of 16,000, 20,000, and 24,000
rpm. Samples were detected using absorption optics at 280 nm,
and equilibrium was assessed by comparing successive scans us-
ing the MATCH program. Raw data were edited using the REEDIT
program, and data analysis was carried out using the NONLIN pro-
gram. Global data fits were carried out to calculate the effective mo-
lecular weight in an ideal single-species model. Models for associat-ing molecules used the calculated s values from the monomer
molecular weight and fitted to dissociation constants. The quality
of the fits was assessed by examining residuals and minimizing
the fit variance.
Coimmunoprecipitation of Snf1
The yeast strains prepared for coimmunoprecipitation experiments
were as follows:
No tag (YMFS182): MATa ura3 leu2-3,112 his3-11,15 trp1-1
ade2-1 can1-100 snf1::his5+ [pRS316] [pRS315]
Snf1 Wild-type (YMFS183): MATa ura3 leu2-3,112 his3-11, 15
trp1-1 ade2-1 can1-100 snf1::his5+ [pRS316 SNF1-23FLAG]
[pRS315 SNF1-23HA]
Snf1 K84R (YMFS185): MATa ura3 leu2-3,112 his3-11, 15 trp1-1
ade2-1 can1-100 snf1::his5+ [pRS316 snf1K84R-23FLAG]
[pRS315 snf1K84R-23HA]
Snf1 I257E (YMFS193): MATa ura3 leu2-3,112 his3-11, 15 trp1-1
ade2-1 can1-100 snf1::his5+ [pRS316 snf1I257E-23FLAG]
[pRS315 snf1I257E-23HA]
Snf1 F261E (YMFS195): MATa ura3 leu2-3,112 his3-11, 15 trp1-1
ade2-1 can1-100 snf1::his5+ [pRS316 snf1F261E-23FLAG]
[pRS315 snf1F261E-23HA]
Strains containing two alternatively tagged versions of wild-type
or mutant SNF1 on separate plasmids (SNF1-23HA and SNF1-
23FLAG) were grown in SC-uracil-leucine media to mid-log phase.
Cells were then harvested and resuspended in lysis buffer (50 mM
NaPO4 [pH 7.2], 50–400 mM NaCl, 1 mM EDTA, 10% glycerol,
0.1% Triton X-100, 10 mM NaF, 10 mM b-glycerophosphate, 1 mM
1,10-phenanthroline, 1 mM PMSF, Complete Mini, EDTA-free prote-
ase inhibitor cocktail tablets [Roche]), and lysis was performed by
mechanical disruption using a Mini-beadbeater (Biospec). Lysates
were then clarified by centrifugation, and equal amounts of protein
from each strain were immunoprecipitated with anti-FLAG (M2) or
anti-HA (HA-7) agarose (Sigma). Bound proteins were washed (with
lysis buffer containing the same NaCl concentration used for lysis)
and eluted by boiling in SDS-PAGE sample buffer. Eluted proteins
were run on 10% SDS-PAGE gels and transferred to nitrocellulose
for Western analysis. Western blotting was performed with anti-
FLAG (M2) HRP conjugate (Sigma) or anti-HA (3F10) HRP conjugate
(Roche) antibodies, following the manufacturer’s recommendations.
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